L’impact économique de l’hépatite C en Australie

Le rapport conclut que l’investissement dans les nouveaux traitements moins onéreux contre l’hépatite C permettrait de guérir plus de personnes atteintes de cette maladie chronique et apportera, à long-terme, des bénéfices économiques significatifs à la société.Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

Hepatitis Australia's mission is to ensure the needs of Australians affected by, or at risk of, viral hepatitis are met. The hepatitis C virus attacks the liver and can lead to a long-term, potentially life-threatening liver disease. The very low level of hepatitis C treatment in Australia contributes to a growing burden of disease and rising health care costs.

This report comes at a critical time. The outlook is bright for many people living with hepatitis C. New hepatitis C medications with significantly improved cure rates are becoming a reality after many years of minimal change in the treatment landscape.

The report concludes that investment in new hepatitis C treatment will cure more people of a chronic and costly condition and provide substantial economic benefits for society in the long term.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.